Themis Bioscience and Merck join forces to develop vaccines

22 August 2019
themisbig

Privately-owned Austrian biotech Themis Bioscience announced today a research collaboration and exclusive license agreement with Merck & Co (NYSE: MRK), known as MSD outside the USA and Canada, for the discovery and development of undisclosed vaccine candidates using Themis’ measles virus vector-based platform, marking the Vienna-based firm’s first deal with a pharma major.

“Given the versatility of our immune-modulation platform and our proven ability to rapidly generate product candidates across a broad range of infectious disease and cancer indications, our partnership with MSD, a global leader in vaccine development, validates the potential of our measles virus-based technology,” said Dr Erich Tauber, chief executive of Themis Bioscience.”

Deal potentially worth $200 million to Themis

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Company News Directory

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology